Relationship between Anaplastic Lymphoma Kinase Inhibitors and Epileptic Seizure Disorder: A Post-Marketing Surveillance Study
Oncology · 2024
DOI: 10.1159/000539426 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Yoshihiro Noguchi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan. Hauptthemen laut MEDLINE: Anaplastic Lymphoma Kinase, Lactams, Carbazoles, Piperidines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Introduction
Anaplastic lymphoma kinase (ALK) has been to be involved in the uptake and regulation of dopamine 2 receptor (D2R), a G protein-coupled receptor expressed in various brain regions. Therefore, it is crucial to understand the relationship between ALK inhibitors and seizures is an important issue. This study investigated the relationship between ALK inhibitors and seizures.
Methods
This study investigated the relationship between ALK inhibitors and seizures through a disproportionality analysis using the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). The target drugs were the ALK inhibitors crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib. The seizures covered were defined high-level group term (HLGT): “Seizures (incl. subtype)” including high-level term (HLT): “seizures and seizure disorders NEC.” This study used the information component (IC), a signal score, as a Bayesian statistical method for disproportionality analysis. The signal detection criteria used in this study were the same as those reported previously: a lower limit of 95% credible interval (CrI) for IC >0.
Results
The signal scores of '“seizures and seizure disorders not elsewhere classified (NEC)” “for each ALK inhibitor were crizotinib (IC: −0.00052, 95% CrI: −0.38–0.27), ceritinib (IC: 1.18, 95% CrI: 0.68–1.54), alectinib (IC: 0.68, 95% CrI: 0.19–1.02), brigatinib (IC: 1.04, 95% CrI: 0.32–1.54), and lorlatinib (IC: 0.82, 95% CrI: 0.11–1.32). On the other hand, “generalized tonic-clonic seizures,” “partial simple seizures NEC,” “absence seizures,” and “partial complex seizures” had no or few reported cases, and no signal was detected.
Conclusion
To our knowledge, this is the first report to evaluate the relationship between ALK inhibitors and seizures using post-marketing surveillance data. These results suggest that ceritinib, alectinib, brigatinib, and lorlatinib, which are highly brain-migrating drugs, are associated with seizures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
- Laboratory of Medical Collaborative Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
- Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan.
Zitieren
APA
Noguchi, Y., Asano, H., Masuda, R., Teshigawara, Y., Go, M., Kimura, M., Usami, E., & Yoshimura, T. (2024). Relationship between Anaplastic Lymphoma Kinase Inhibitors and Epileptic Seizure Disorder: A Post-Marketing Surveillance Study. Oncology. https://doi.org/10.1159/000539426
Vancouver
Noguchi Y, Asano H, Masuda R, Teshigawara Y, Go M, Kimura M, et al. Relationship between Anaplastic Lymphoma Kinase Inhibitors and Epileptic Seizure Disorder: A Post-Marketing Surveillance Study. Oncology. 2024. doi:10.1159/000539426
BibTeX
@article{Noguchi2024,
author = {Noguchi, Yoshihiro and Asano, Hiroki and Masuda, Rikuto and Teshigawara, Yuta and Go, Makiko and Kimura, Michio and Usami, Eiseki and Yoshimura, Tomoaki},
title = {Relationship between Anaplastic Lymphoma Kinase Inhibitors and Epileptic Seizure Disorder: A Post-Marketing Surveillance Study},
journal = {Oncology},
year = {2024},
doi = {10.1159/000539426}
}
EUVIMED